Nab-paclitaxel and S-1
Sponsors
Aiping Zhou, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Conditions
Advanced Pancreatic CancerBorderline Resectable Pancreatic CancerLocally Advanced Pancreatic Cancer
Phase 2
Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer
CompletedNCT03415802
Start: 2015-05-11End: 2019-07-11Updated: 2021-02-01
Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer
NCT03815461
Start: 2019-02-01End: 2023-10-02Target: 60Updated: 2019-01-25
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer
NCT03850769
Start: 2019-05-01End: 2022-04-30Target: 60Updated: 2020-03-10
Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer
NCT03885219
Start: 2019-05-01End: 2022-04-30Target: 60Updated: 2020-03-10